Navigation Links
ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/6/2008

illion and $37.4 million for the corresponding periods in 2006. The 2007 increase primarily resulted from higher sales and marketing expenses associated with the expansion of ISTA's sales force in early 2007. Stock-based compensation expenses included in SG&A for the fourth quarter and for the year ended December 31, 2007 were $0.8 million and $2.5 million, respectively.

The net loss for the fourth quarter and year ended December 31, 2007, was $9.9 million (or $0.30 per share) and $38.2 million (or $1.29 per share), respectively, compared with a net loss of $6.4 million (or $0.25 per share) and $38.4 million (or $1.48 per share) for the same periods in 2006. At December 31, 2007, ISTA had cash and short-term investments of $46.1 million.

2007 Corporate Highlights

-- Increased net revenue by 56% and 78% as compared to the fourth quarter

of 2006, and year ended December 31, 2006, respectively

-- Filed an NDA with the FDA for Xibrom QD (once-daily) in December of

2007 after announcing, earlier in the year, positive Phase III results

for Xibrom QD as a treatment for inflammation, pain, and photophobia

following cataract surgery

-- Announced statistically significant Phase II/III study results for

Bepreve in treating ocular itching and clinical improvement in redness

and initiated both the Bepreve ocular safety study and the second

Phase III study

-- Announced positive results from the ecabet sodium Phase IIb study for

the treatment of dry eye syndrome

-- Successfully completed $36.7 million financing through the private

placement of 5.25 million shares of common stock with institutional

accredited investors at a purchase price of $7.00 per share

-- Expanded pipeline in allergy treatments by licensing exclusive North

American rights to nasal dosage forms of bepotastine, an

investigation
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ADVENTRX Pharmaceuticals to Report Fourth Quarter and Year End 2007 Results
2. Acura Pharmaceuticals, Inc. Reports 2007 4th Quarter and Annual Financial Results; Sets 2008 Expectations
3. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
4. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
5. MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
6. SGX Pharmaceuticals Schedules Teleconference and Webcast for Fourth Quarter and Full Year 2007 Results
7. NPS Pharmaceuticals to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
8. NuRx Pharmaceuticals Retains Russo Partners for Investor Relations, Corporate Communications Counsel
9. MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 2008
10. Wyeth Pharmaceuticals Ends Collaboration Agreements with Solvay Pharmaceuticals for Bifeprunox and Other Compounds
11. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)...  Faced with increasing challenges such as costly ... symptomatic, the global healthcare industry today is gradually ... curing or significantly changing the course of a ... regenerative medicine as a viable alternative. ... health with the potential to resolve unmet medical ...
(Date:7/27/2015)... ... July 27, 2015 , ... Production of high tenacity ... past few years in the EU. For instance, it surpassed the EUR 106 million ... million mark in 2010. Germany is a major producer, while Italy is a key ...
(Date:7/27/2015)... , July 27, 2015 According ... by Type (Home-brew Media, Pre-formulated Media), by Application (Biobanking, Regenerative ... , Europe , Asia-Pacific ... 2019", The global biopreservation media market was valued at $247.7 ... $571.5 million by 2019, at a CAGR of 18.2% between ...
(Date:7/26/2015)... Maine (PRWEB) , ... July 26, 2015 , ... ... release of its VALIDATE® ANEMIA calibration verification / linearity test kit. The VALIDATE® ... Each VALIDATE® ANEMIA kit is prepared using the CLSI recommended “equal delta” ...
Breaking Biology Technology:Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 2Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 4Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 5High Tenacity Filament Yarn of Viscose Rayon Consumption to Grow Swiftly in the EU, Forecasts BAC Reports in New Study Available at MarketPublishers.com 2Global Biopreservation Media Market to be Worth $571.5 Million by 2019 2Global Biopreservation Media Market to be Worth $571.5 Million by 2019 3Maine Standards Company, LLC Announces Release of VALIDATE® ANEMIA Calibration Verification / Linearity Test Kit 2
... Pharmacopeia,(Nasdaq: PCOP ), an innovator in the discovery ... Dr. Leslie J. Browne,President and Chief Executive Officer, will ... Healthcare Conference hosted by,BMO Capital Markets. The conference will ... in New York City., Dr. Browne,s presentation will ...
... Lexicon,Pharmaceuticals, Inc. (Nasdaq: LXRX ) today announced that ... Piper Jaffray 19th Annual,Health Care Conference at The Pierre ... 2007 at 8:30 a.m. Eastern Time., A live ... website at http://www.lexpharma.com . An archived version of ...
... Archer Daniels Midland,Company (NYSE: ADM ) ... elected to retire by year end., In ... to advance the,Company,s business strategy for Asian investments ... Company,s strategic planning group,under the direction of Steve ...
Cached Biology Technology:Pharmacopeia To Present at BMO Capital Markets' Seventh Annual Focus on Healthcare Conference 2Pharmacopeia To Present at BMO Capital Markets' Seventh Annual Focus on Healthcare Conference 3Lexicon Pharmaceuticals to Present at the Piper Jaffray 19th Annual Health Care Conference 2ADM Executive Vice President Bill Camp to Retire 2
(Date:7/7/2015)... MOUNTAIN VIEW, Calif. , July 7, 2015 ... mobile biometrics market, Frost & Sullivan recognizes Credence ... & Sullivan Entrepreneurial Company of the Year ... product suite to aid in its mission of ... and under-recognized populations globally. As Credence ID was ...
(Date:7/2/2015)... , June 25, 2015 ... of the "Next Generation Biometrics Market by Application, ... report to their offering. The next ... by 2020, at a CAGR of 17.9% between 2015 ... leading application for the market. Safran SA ...
(Date:6/30/2015)... -- Genisphere announced Tom Bliss ... develop Genisphere,s therapeutics capabilities and portfolio. Mr. Bliss comes ... of the last 25 years in leadership positions at ... & Johnson. Tom started his career in Investment Banking, ... He graduated from Dartmouth College with a BA in ...
Breaking Biology News(10 mins):Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3
... Women,s skulls are thicker than men,s, but they both ... of a new imaging study of 3000 people published ... detailed results could help in the design of more ... and other accidents. Jesse Ruan of the Ford ...
... MADISON - The deadly Ebola virus, an emerging public ... ranks among the most feared of exotic pathogens. ... or treatments are available, scientists studying the agent have ... limiting research to a few highly specialized labs and ...
... the University of Exeter has highlighted the problems ... projects. Published online in the journal Biological Conservation, ... captive carnivores that are released into their natural ... carnivores survives in the wild, with most deaths ...
Cached Biology News:Skull survey could improve vehicle safety 2Ebola virus disarmed by excising a single gene 2Ebola virus disarmed by excising a single gene 3Captive carnivores not up to wild living 2
Carbonate-Bicarbonate Buffer Capsules. For use in coating ELISA plates. Dissolve contents of 1 capsule in 100 ml deionized water to yield 0.05 M carbonate-bicarbonate buffer, pH 9.6....
Immunogen: Synthetic peptide: S(399) P W S E L E F Q F P D D K D P V W E F(418) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Immunogen: C terminus [VQLKRSKNDSKPYC] of cardiac elav-type RNA-binding protein (ETR-3) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Borosilicate Glass. Certified for use with the Beacon 2000 Systems, 1,000 tubes/case...
Biology Products: